PharmaVoice 100s: Tech wizards

The leaders paving the way to pharma’s future with state-of-the-art digital solutions.

By Karissa Waddick • Oct. 9, 2023

Where have all the unicorns gone? A look at 4 billion-dollar biotechs

Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.

By Alexandra Pecci • Oct. 3, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

The ALS therapy keeping the human pig heart transplant pumping

Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.

By Kelly Bilodeau • Oct. 2, 2023

Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.

By Karissa Waddick • Sept. 27, 2023

Do humans have a place in pharma’s AI future?

From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

By Michael Gibney • Sept. 26, 2023

Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

By Alexandra Pecci • Sept. 26, 2023

Elderly exclusion: Clinical trials still fall short enrolling older adults

Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.

By Kelly Bilodeau • Sept. 25, 2023

Three years after an FDA rejection, DBV sees a path for its peanut patch

Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.

By Karissa Waddick • Sept. 22, 2023

The 2023 PharmaVoice 100

This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.

By Julia Himmel • Sept. 19, 2023

Endangered horseshoe crabs could lead the charge in pharma’s animal-free future

An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.

By Kelly Bilodeau • Sept. 18, 2023

Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’

Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.

By Michael Gibney • Sept. 15, 2023

In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

By Michael Gibney • Sept. 14, 2023

Catching up with 2022 PharmaVoice 100 honorees

Tapping into our growing community for expertise and inspiration.

By Meagan Parrish • Sept. 13, 2023

Immuneering takes aim at cancer’s ‘superhighway’

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

By Kelly Bilodeau • Sept. 11, 2023

Why this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery

Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.

By Alexandra Pecci • Sept. 6, 2023

Hope sputters for emerging anti-TIGIT drug class

Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.

By Kelly Bilodeau • Sept. 5, 2023

4 modernized functions every sponsor needs for study startup

Explore four modern tech capabilities designed to help decrease cycle times, improve processes and compliance and mitigate site burdens.

By Stuart Cotter, VP Product Innovation and Strategy, Advarra • Sept. 5, 2023

A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

By Meagan Parrish • Sept. 1, 2023

Medicare named the first 10 drugs up for negotiation. Now what?

The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.

By Karissa Waddick • Aug. 30, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

Why pharma isn’t done tackling migraines

In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options. 

By Kelly Bilodeau • Aug. 28, 2023

‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax

New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.

By Michael Gibney • Aug. 24, 2023

Henrietta Lacks’ immortal cells put biopharma profits under a microscope

The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.

By Michael Gibney • Aug. 23, 2023

Brii Biosciences aims to come up big where Sage and Biogen fell short

The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

By Kelly Bilodeau • Aug. 21, 2023

Behind Flagship Pioneering’s triumphs and tribulations

From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.

By Karissa Waddick • Aug. 18, 2023